EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Ofatumumab for treating autoimmune nodopathy

Jianian Hu iD, Yongsheng Zheng iD, Chong Sun, Jian Sun, Jianying Xi, Sushan Luo, Kai Qiao, Chongbo Zhao, Jie Lin

Journal of the Peripheral Nervous System · 2025

DOI: 10.1111/jns.12679 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Journal of the Peripheral Nervous System, 2025. Verfasst von Jianian Hu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Huashan Hospital Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Antibodies, Monoclonal. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Shanghai Municipal Science and Technology Major Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims To investigate the treatment of ofatumumab in autoimmune nodopathy (AN).

Methods

An open‐label, prospective, observational study was conducted in patients with AN. The regimen was 20 mg ofatumumab subcutaneously on day 0, 7, 14, 28, and subsequently every 4 weeks in a total of 24 weeks. The primary endpoint of the study was the proportion of patients with confirmed clinical improvement.

Results

All of the eight patients (100%) improved at Week 24. The median time to improvement was 8 (IQR: 7–10) weeks. The four patients previously treated with rituximab and two with irregular injections of ofatumumab (OFA) improved. At Week 24, the adjusted INCAT score, MRC sum score, cI‐RODS, and grip strength in nondominant hand significantly improved from baseline. In nerve conduction studies, all of the six patients with available data (100%) improved. The median sNfL significantly reduced from baseline at Week 8. Anti‐paranodal antibody in seven patients with anti‐NF155 antibodies reduced from baseline at Week 20. In seven of the eight patients, CD19+ B cells were significantly reduced at Week 4. No serious adverse events were reported.

Interpretation

The regimen was 20 mg ofatumumab subcutaneously on day 0, 7, 14, 28, and every 4 weeks from Week 4, in a total of 24 weeks. The ofatumumab therapy may provide a more convenient and safer treatment for patients with AN, while serving as an effective alternative for those who did not respond to rituximab.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalHumansFemaleAntibodies, Monoclonal, HumanizedMiddle AgedMaleAdultProspective StudiesAged

Stichwörter der Autor:innen

chronic inflammatory demyelinating polyradiculoneuropathyofatumumabperipheral neuropathyprospective observational studytreatment

Substanzen

ofatumumabAntibodies, Monoclonal, HumanizedAntibodies, Monoclonal

Autor:innen und Institutionen

  • Department of Neurology, Huashan Hospital Fudan University, Shanghai, China.
  • Rare Disease Center, Huashan Hospital Fudan University, Shanghai, China.
  • National Center for Neurological Disorders (NCND), Shanghai, China.

ORCID-Profile: Jianian Hu, Yongsheng Zheng

Förderung

  • Shanghai Municipal Science and Technology Major Project

Zitieren

APA

Hu, J., Zheng, Y., Sun, C., Sun, J., Xi, J., Luo, S., Qiao, K., Zhao, C., & Lin, J. (2025). Ofatumumab for treating autoimmune nodopathy. Journal of the Peripheral Nervous System. https://doi.org/10.1111/jns.12679

Vancouver

Hu J, Zheng Y, Sun C, Sun J, Xi J, Luo S, et al. Ofatumumab for treating autoimmune nodopathy. Journal of the Peripheral Nervous System. 2025. doi:10.1111/jns.12679

BibTeX
@article{Hu2025,
  author = {Hu, Jianian and Zheng, Yongsheng and Sun, Chong and Sun, Jian and Xi, Jianying and Luo, Sushan and Qiao, Kai and Zhao, Chongbo and Lin, Jie},
  title = {Ofatumumab for treating autoimmune nodopathy},
  journal = {Journal of the Peripheral Nervous System},
  year = {2025},
  doi = {10.1111/jns.12679}
}
Kostenlos starten →